Share
After treatment starts, it is natural to look for signs that it is helping. A lump seems smaller. A blood marker rises slightly. You feel better—or worse because the treatment itself is difficult. Which observation should you trust?
Doctors usually combine several sources of information. What counts as success also depends on the goal: shrinking visible disease is assessed differently from treatment given after surgery to reduce recurrence risk. The first useful question is: “What are we using to judge whether treatment is helping, and when will we assess it?”
The treatment goal determines the measure
When cancer is measurable, the team can follow its size or activity, symptoms and disease-specific tests. After complete surgery, there may be nothing visible to measure. Additional treatment then aims to reduce future recurrence risk; a normal scan cannot show whether an individual dose removed microscopic disease.
Treatment before surgery is different again. Scans can assess changes before an operation, while examination of the removed tissue can provide further information afterwards. Understanding the goal explains why a clear scan is not always a reason to stop treatment.
Why the baseline matters
Response is a comparison with an appropriate starting point. That may include scans performed shortly before treatment, a palpable lump, blood markers, symptoms or marrow findings.
Keep the actual images, not only reports. Comparing the same areas using similar methods helps distinguish a genuine change from a measurement difference. A scan performed well before the first treatment may not accurately represent disease burden on the day treatment began.
Ask which scan is the baseline and what changes would be considered meaningful. A millimetre difference described in a report can feel alarming but does not always imply a clinically important change.
Symptoms and examination remain useful
Improved pain, appetite, breathing and daily function can suggest benefit. An accessible tumour may become smaller. These outcomes matter even before formal reassessment.
However, symptoms have several possible causes. Fatigue can reflect cancer, anaemia, poor sleep or treatment. Pain may improve because of better pain relief without a change in tumour size. Nausea after an infusion can occur even while the cancer responds.
Describe changes rather than interpreting them alone: when a symptom started, its severity and its effect on eating, walking or sleep. New or severe symptoms should be reported promptly, not saved for the next scheduled scan.
What can CT, MRI and PET-CT show?
CT and MRI help assess the size and extent of many tumours. PET-CT provides information about uptake of a tracer and is useful in selected cancers and situations. No single scan is best for every disease.
PET activity can also occur with inflammation, infection or healing. A residual mass can sometimes represent scar rather than active cancer. Interpretation therefore depends on the cancer, treatment, timing and imaging method. A clear scan is reassuring within its limits, but no scan detects every microscopic cancer cell.
Ask why the recommended scan is appropriate and how its result could change treatment. More expensive or more frequent imaging is not automatically more informative.
What do the response labels mean?
For many solid tumours, standard criteria such as RECIST help describe changes consistently. Other cancers use different systems, so the terminology must be interpreted in context.
If the table extends beyond your screen, swipe or scroll sideways to read every column.
Result | Usual meaning | Important qualification |
|---|---|---|
Complete response | Assessable disease disappears according to the criteria used | Not automatically the same as cure |
Partial response | Sufficient shrinkage to meet the relevant threshold | Some cancer remains |
Stable disease | Neither sufficient shrinkage nor sufficient worsening to meet the other categories | Stability may be a worthwhile benefit |
Progressive disease | Sufficient growth, new disease or other qualifying evidence of worsening | The full clinical picture still matters |
“Stable” can disappoint someone hoping for disappearance. Yet holding a previously growing cancer under control can be a meaningful result, particularly when symptoms are controlled and treatment is tolerable. The relevant comparison is what the cancer would otherwise be expected to do.
Why one tumour-marker result rarely settles the answer
PSA, CA-125, CA19-9, AFP and other markers are useful in particular cancers. Not all cancers produce a useful marker, and normal levels do not exclude disease. Some markers can be affected by non-cancer conditions.
Doctors usually look at trends alongside symptoms, scans and treatment timing. A small rise might lead to a repeat test rather than an immediate change of medicine. A persistent or substantial rise may be more concerning, but still needs interpretation.
Ask whether the marker was elevated before treatment, whether it reliably tracks your disease and what else might explain a change. A number affected by inflammation or obstruction should not be treated as a precise tumour-volume measurement.
What can pathology show after treatment before surgery?
The pathologist examines the removed tissue for viable cancer. A pathological complete response means no remaining cancer is found in the defined tissues under that disease’s criteria. Its significance and effect on further treatment differ by cancer.
This is not identical to a complete scan response. Imaging can look clear despite microscopic residual disease, or show an abnormality that contains no viable tumour. An excellent scan therefore does not automatically mean a planned operation can be cancelled.
Margins, lymph nodes and other pathological findings also matter. Ask the team to explain the whole result rather than focus on a single reassuring or alarming phrase.
Why can immunotherapy complicate scan interpretation?
A small minority of patients have apparent early worsening followed by response, called pseudoprogression. It is recognised but uncommon. It is not the usual explanation for every enlarging tumour during immunotherapy.
True progression, infection and treatment-related inflammation need consideration. A clinically stable patient may sometimes have a confirmation scan before treatment changes. Someone becoming significantly more unwell should not simply be told that worsening means the immune system is working.
Special immune-response rules help standardise research and inform interpretation. They do not create an obligation to continue treatment despite clinical deterioration.
Where do liquid biopsy and residual-disease tests fit?
Blood tests detecting tumour DNA can help answer specific questions. They may identify treatment targets or resistance, and in selected cancer pathways they can guide decisions about molecular residual disease. Their role is different from an ordinary protein tumour marker.
The limits remain important: a negative result does not exclude all disease, and a molecular change is not a universal instruction to alter treatment. The test, cancer, timing and evidence for the proposed action must match. Some applications have entered defined clinical pathways; others remain investigational.
Ask what the team will do with a positive, negative or inconclusive result before ordering repeated tests. A test without an agreed consequence may add anxiety rather than clarity.
How often should treatment be reassessed?
There is no universal scan schedule. Reassessment may follow a planned number of cycles or disease-specific milestone. New symptoms can require earlier review. Scanning too soon may create confusion, while ignoring deterioration until a distant appointment can miss an important problem.
Agree on the likely schedule and what would trigger earlier assessment. If a result is uncertain, ask for the next step: image comparison, repeat testing, radiology review, biopsy or reassessment after an appropriate interval. Uncertainty should lead to a plan, not an unexplained wait.
What happens if treatment is not helping enough?
The next decision depends on clear progression, symptoms, toxicity and available alternatives. Sometimes the systemic treatment changes; sometimes a particular disease site can be treated locally while the broader treatment continues. Sometimes reducing treatment burden becomes the priority.
Ask what has changed and whether another test is likely to identify a useful option. A different drug is not automatically better simply because it is different. Expected benefit and its effect on daily life remain central.
Frequently asked questions
Do stronger side effects mean stronger cancer control?
No. Toxicity is not a reliable personal measure of tumour response. Report side effects so they can be treated; do not endure serious symptoms as proof that a medicine is active.
Does a clear PET-CT mean I am cured?
Not necessarily. It means no abnormality meeting that assessment’s criteria is detected at that time. Cure depends on the disease, treatment and subsequent course.
Can some lesions shrink while another grows?
Yes. Different areas of cancer may behave differently. A mixed response needs specialist interpretation and may call for a different strategy from widespread progression.
How can I manage anxiety while waiting?
Know when the result will be discussed and avoid repeatedly interpreting partial reports without context. Tell the team if anxiety is interfering with sleep or function. A predictable review plan is often more helpful than repeated unscheduled testing.
Response assessment is a conversation about evidence, symptoms and treatment goals—not just whether one number has gone up or down.
Medical information notice: This information is for general education and does not replace individual medical advice. Cancer treatment depends on the diagnosis, stage, tumour biology, previous treatment, general health and individual circumstances.
